Kidney stones and gallstones may increase the risk for prostate cancer, which could have implications for disease monitoring and prevention in specific populations. Patients with kidney stones or ...

In the United States, patients with renal cell carcinoma are more likely to die from COPD than the general population. Chronic obstructive pulmonary disease (COPD) is a major cause of death among ...

In 2023, 35.6% of patients received androgen-deprivation therapy alone. Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with metastatic hormone ...

Platelet level may indicate response to 177Lu PSMA therapy in radium-223 treated patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu PSMA) appears effective following treatment with radium 223 (223 ...

Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with incident bipolar disorder (BD), accordi ...

Pain intensity linked to increased likelihood of using cigarettes, e-cigarettes, cannabis, lower likelihood of alcohol use ...

Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on ...

The odds of major perioperative bleeding were increased 18.1-fold for patients who underwent emergent hepatic surgery, 10.9-fold for emergent splenic surgery, and 9.6-fold for emergent pancreatic ...

Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...

Burnout in US oncologists has increased over the past 10 years, according to results of 2 surveys. 1 Researchers compared results of a 2023 survey of 328 oncologists to results of a 2013 survey of ...

Risk for death significantly lower for patients with return of serum testosterone to normal range value. (HealthDay News) — Serum testosterone (T) recovery to normal levels is associated with a ...

According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.